MAS825
- Generic Name
- MAS825
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 1
- Registration Number
- NCT06309823
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT06097663
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Vanderbilt University Medical Cent, Nashville, Tennessee, United States
🇩🇪Novartis Investigative Site, Muenchen, Germany
A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT04665154
- Locations
- 🇬🇧
Novartis Investigative Site, Mere Way, Nottingham, United Kingdom
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT04641442
- Locations
- 🇺🇸
Cincinnati Children's Hospital, Cincinnati, Ohio, United States
🇺🇸Children´s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Texas Children´s Hospital, Houston, Texas, United States
Study of Efficacy and Safety of MAS825 in Patients With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT04382651
- Locations
- 🇺🇸
Novartis Investigative Site, Mesquite, Texas, United States
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 248
- Registration Number
- NCT03827798
- Locations
- 🇺🇸
Olympian Clinical Research ., Clearwater, Florida, United States
🇺🇸Park Avenue Dermatology, PA, Orange Park, Florida, United States
🇺🇸Advanced Medical Research, Sandy Springs, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.